Inmode Ltd Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.57 Intrinsic Value $12.19median of 5 methods · middle span $10-$15based on filings through 31 Dec 2025 Market Price $14.05Price as of 1 Oct 2026 Near fair valueIntrinsic value is 13% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $808.5M Enterprise Value $506M Shares Outstanding 65.4M diluted Moat Rating Wide Next Earnings Date4 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary InMode Ltd. presents a classic value-trap profile where an exceptionally cheap valuation and a massive cash cushion are offset by structural headwinds. The company sits on a fortress balance sheet with over $530 million in cash and marketable securities (representing roughly 60% of its market capitalization) and virtually no debt. However, its core minimally invasive radiofrequency (RF) aesthetics business is facing flat-to-declining organic growth, severe gross margin compression (dropping from historical mid-80s to 75%), and strategic uncertainty as it pivots into highly competitive, lower-margin laser and dry-eye markets. While the downside is heavily protected by the cash hoard and active share buybacks, a re-rating is unlikely until the core RF business stabilizes and management demonstrates a high-return deployment of its capital. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$15.00 Mean target$16.17 High · most bullish analyst$17.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $11.0015% Macroeconomic pressures further depress discretionary consumer spending, causing a sharp decline in system sales. Gross margins decay below 73% due to aggressive competitor pricing and an unfavorable product mix. Management misallocates its cash hoard on a value-destructive acquisition, leading to a permanent impairment of capital and a further discount on the stock. Base CaseCentral scenario $15.3360% InMode executes in line with its FY2026 guidance, delivering flat revenue growth of $365M-$375M and maintaining gross margins in the 75%-76% range. The company continues to return capital defensively through share buybacks, which supports the stock price but fails to trigger a major multiple expansion due to ongoing competitive pressures and a soft macroeconomic environment for discretionary aesthetic treatments. Bull CaseUpside scenario $19.0025% The aesthetic market recovers faster than expected, driving a surge in elective procedures. InMode's newly launched platforms (such as OptimasMAX) gain rapid adoption, restoring gross margins back toward 80%. Additionally, management successfully deploys its cash hoard into a highly accretive, high-growth medical technology acquisition, unlocking significant non-organic growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |